| Title | Genetic and Cystic Kidney Disorders |
| Publication Type | Journal Article |
| Year of Publication | 2026 |
| Authors | Weimbs, T, Pastor-Soler, NM, Kovarik, JJ |
| Journal | Integrative Nephrology (M. Isreb, Editor) |
| Volume | Text Book |
| Pagination | 407–431 |
| ISBN Number | 978-3-032-24333-1 |
| Abstract | Genetic kidney diseases represent a diverse spectrum of inherited disorders that impact renal structure and function, often culminating in chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Among these, Autosomal- Dominant Polycystic Kidney Disease (ADPKD) is the most prevalent, affecting over 10 million individuals globally. While traditionally considered unmodi!- able due to their genetic origins, recent advances suggest that many aspects of disease progression across genetic kidney disorders, including ADPKD, may be signi!cantly influenced by modi!able factors such as diet, metabolic health, and environmental exposures. This chapter explores the emerging framework of integrative nephrology in the context of genetic kidney diseases, highlighting shared mechanisms that drive disease progression such as renal inflammation, !brosis, metabolic dys- regulation, and crystal-induced tubular injury. We present ADPKD as a paradigm for integrative management, focusing on conservative, lifestyle-based interven- tions such as therapeutic carbohydrate restriction, ketogenic metabolic therapy (KMT), and the avoidance of dietary and environmental nephrotoxins. Clinical and preclinical studies suggest that these strategies can improve quality of life and potentially slow or halt disease progression. Emphasis is placed on patient-centered care, proactive education, and the importance of addressing the psychosocial impact of receiving a genetic diagno- sis. By reframing the management of genetic kidney disorders through the lens of integrative nephrology, this chapter advocates for a hopeful, patient-centered, actionable disease management approach that complements pharmacologic ther- apy and empowers both clinicians and patients to effect a positive change on kidney disease progression. |
| URL | https://link.springer.com/chapter/10.1007/978-3-032-24334-8_14 |
| DOI | 10.1007/978-3-032-24334-8_14 |

